Detalhe da pesquisa
1.
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
Lancet
; 401(10379): 821-832, 2023 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36774933
2.
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
Prostate
; 83(4): 376-384, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564933
3.
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.
BMC Cancer
; 16: 135, 2016 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26906039
4.
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
J Neurooncol
; 127(3): 569-79, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26847813
5.
Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).
Curr Oncol Rep
; 18(12): 72, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27812861
6.
Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer.
Front Oncol
; 14: 1385466, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38774416
7.
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.
Target Oncol
; 18(5): 639-641, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37659025
8.
Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2.
Anticancer Drugs
; 23(2): 239-46, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22112931
9.
Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Cancers (Basel)
; 14(4)2022 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35205837
10.
Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
Oral Oncol
; 134: 106087, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36126605
11.
Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study).
Lung Cancer
; 173: 83-93, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36162227
12.
Molecular basis of hypertension side effects induced by sunitinib.
Anticancer Drugs
; 22(1): 1-8, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20938340
13.
Proteomics as a Complementary Technique to Characterize Bladder Cancer.
Cancers (Basel)
; 13(21)2021 Nov 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34771699
14.
Blood-based protein biomarkers in bladder urothelial tumors.
J Proteomics
; 247: 104329, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34298186
15.
Detection of Circulating Serum Protein Biomarkers of Non-Muscle Invasive Bladder Cancer after Protein Corona-Silver Nanoparticles Analysis by SWATH-MS.
Nanomaterials (Basel)
; 11(9)2021 Sep 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34578700
16.
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial.
Mol Oncol
; 15(1): 43-56, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33107189
17.
Identification of a Profile of Neutrophil-Derived Granule Proteins in the Surface of Gold Nanoparticles after Their Interaction with Human Breast Cancer Sera.
Nanomaterials (Basel)
; 10(6)2020 Jun 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32586001
18.
Potential clinical applications of the personalized, disease-specific protein corona on nanoparticles.
Clin Chim Acta
; 501: 102-111, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31678275
19.
Proteomic investigation on bio-corona of Au, Ag and Fe nanoparticles for the discovery of triple negative breast cancer serum protein biomarkers.
J Proteomics
; 212: 103581, 2020 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31731051
20.
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
Lung Cancer
; 150: 62-69, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33070053